KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Amortization of Deferred Charges (2017 - 2025)

Historic Amortization of Deferred Charges for Emergent BioSolutions (EBS) over the last 9 years, with Q3 2025 value amounting to $2.5 million.

  • Emergent BioSolutions' Amortization of Deferred Charges rose 13731.34% to $2.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.4 million, marking a year-over-year decrease of 1376.15%. This contributed to the annual value of $7.4 million for FY2024, which is 6525.82% down from last year.
  • According to the latest figures from Q3 2025, Emergent BioSolutions' Amortization of Deferred Charges is $2.5 million, which was up 13731.34% from $2.4 million recorded in Q2 2025.
  • Over the past 5 years, Emergent BioSolutions' Amortization of Deferred Charges peaked at $8.9 million during Q2 2023, and registered a low of -$6.7 million during Q3 2024.
  • Over the past 5 years, Emergent BioSolutions' median Amortization of Deferred Charges value was $1.1 million (recorded in 2021), while the average stood at $2.3 million.
  • In the last 5 years, Emergent BioSolutions' Amortization of Deferred Charges soared by 79000.0% in 2023 and then plummeted by 21754.39% in 2024.
  • Over the past 5 years, Emergent BioSolutions' Amortization of Deferred Charges (Quarter) stood at $1.0 million in 2021, then changed by 0.0% to $1.0 million in 2022, then surged by 470.0% to $5.7 million in 2023, then plummeted by 61.4% to $2.2 million in 2024, then rose by 13.64% to $2.5 million in 2025.
  • Its Amortization of Deferred Charges was $2.5 million in Q3 2025, compared to $2.4 million in Q2 2025 and $2.3 million in Q1 2025.